Monarch Casino (MCRI) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +18.03%. A quarter ago, it was expected that this casino operator would post earnings of $1.04 per share when it actually produced earnings of $1.05, delivering a surprise of +0.96%.Over the last four quarters, the ...

Group 1 - Johnson & Johnson reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, but down from $2.82 per share a year ago, representing an earnings surprise of +4.14% [1] - The company achieved revenues of $23.74 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.13% and increasing from $22.45 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 7.3% since the beginning of the year, outperforming the S&P 500's gain of 6.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.75 on revenues of $23.17 billion, and for the current fiscal year, it is $10.64 on revenues of $91.33 billion [7] Group 3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Johnson & Johnson currently holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.14%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.57 per share when it actually produced earnings of $2.77, delivering a surprise of +7.78%.Ov ...

Company Overview - Ouster, Inc. (OUST) shares increased by 14.5% to $28.3 in the last trading session, with a notable trading volume, and have gained 24.2% over the past four weeks [1] - Ouster is experiencing growth due to the rising adoption of LiDAR technology in various sectors including automotive, industrial, robotics, and smart infrastructure [1] Financial Performance - Ouster is projected to report a quarterly loss of $0.48 per share, reflecting a year-over-year change of +9.4%, with expected revenues of $34 million, up 26% from the previous year [2] - The consensus EPS estimate for Ouster has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Comparison - Ouster is part of the Zacks Electronics - Miscellaneous Components industry, where TE Connectivity (TEL) has a consensus EPS estimate of $2.07, showing a year-over-year change of +8.4% [3][4] - TE Connectivity's stock finished the last trading session down 0.4% at $175.44, with a return of 6.5% over the past month [3]

The Trade Desk (TTD) shares rallied 6.6% in the last trading session to close at $80.4. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.4% gain over the past four weeks.The Trade Desk is benefiting from higher adoption of Connected TV (CTV) amid the convergence of the Internet and television programming. This particular growth driver is fast becoming the focus of the company’s growth strategy.This digital-a ...

Investors might want to bet on Robinhood Markets, Inc. (HOOD) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings es ...

Core Viewpoint - Boyd Gaming (BYD) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [4][6]. - Boyd is projected to earn $6.58 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 2.2% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Boyd's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Immunovant, Inc. (IMVT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - For the fiscal year ending March 2026, Immunovant is expected to earn -$2.90 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, where Zacks Rank 1 stocks have generated an average annual return of +25% since 1988 [7]. - The upgrade of Immunovant to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Akebia Therapeutics (AKBA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Si ...

Core Viewpoint - Regions Financial (RF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to buying pressure from institutional investors, resulting in stock price increases [4][5]. Recent Performance and Projections - For the fiscal year ending December 2025, Regions Financial is expected to earn $2.26 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Regions Financial's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].